Compare · GILD vs SNCA
GILD vs SNCA
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Seneca Biopharma, Inc. (SNCA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SNCA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $162.83B.
- GILD has hit the wire 7 times in the past 4 weeks while SNCA has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for SNCA).
- Company
- Gilead Sciences Inc.
- Seneca Biopharma, Inc.
- Price
- $131.21+0.78%
- -
- Market cap
- $162.83B
- -
- 1M return
- -0.02%
- -
- 1Y return
- +14.57%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- n/a
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- SEC Form 13F-HR filed by Gilead Sciences Inc.
- FDA Approval for VEKLURY issued to GILEAD SCIENCES INC
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Latest SNCA
- SEC Form 4 filed by Williams Donald Allen
- SEC Form 4: Trenschel Robert J. was granted 304,479 units of Common Stock
- SEC Form 4 filed by Neal James R
- SEC Form 4: Hallam Thomas was granted 1,592 units of Common Stock
- SEC Form 4: Finley John David was granted 28,718 units of Common Stock
- SEC Form 4 filed by Diaz Stephanie
- SEC Form 4 filed by Dawson Michael John
- SEC Form 3 filed by Williams Donald Allen
- SEC Form 3 filed by Trenschel Robert J.
- SEC Form 3 filed by Neal James R